These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 5165600

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Diacetyl-glucaro-(1 leads to 4) (6 leads to 3)-dilactone (SLA) for prevention of bladder tumor recurrence].
    Shiraishi T, Nihira H.
    Hinyokika Kiyo; 1970 Oct; 16(10):586-92. PubMed ID: 5529995
    [No Abstract] [Full Text] [Related]

  • 4. [Preventive effect of beta-glucuronidase inhibitor (SLA) on recurrence of the bladder tumor].
    Miyagawa M, Harada T, Yoshida O, Kato T.
    Hinyokika Kiyo; 1970 Dec; 16(12):738-44. PubMed ID: 5531642
    [No Abstract] [Full Text] [Related]

  • 5. Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group.
    Newling DW, Robinson MR, Smith PH, Byar D, Lockwood R, Stevens I, De Pauw M, Sylvester R.
    Eur Urol; 1995 Dec; 27(2):110-6. PubMed ID: 7744151
    [Abstract] [Full Text] [Related]

  • 6. [Directed chemotherapy in superficial carcinoma conditioned by the knowledge of relapse factors].
    Oliver F, Llopis B, Vera C, Domínguez C, Vidal J, Gallego J, Jiménez JF.
    Actas Urol Esp; 1988 Dec; 12(5):419-23. PubMed ID: 3218579
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Clinical application of glucarolactone to bladder tumor. II. Effect of SLA on recurrence of bladder tumor].
    Yonese Y.
    Nihon Hinyokika Gakkai Zasshi; 1970 Oct; 61(10):995-1003. PubMed ID: 5529307
    [No Abstract] [Full Text] [Related]

  • 10. [Comparative study of thiotepa, adriamycin and cisplatin in the prophylaxis of recurrence of superficial bladder carcinoma in a group of 217 patients].
    Llopis B, Gallego J, Boronat F, Moreno B, Mompó JA, Jiménez JF.
    Actas Urol Esp; 1986 Oct; 10(4):225-30. PubMed ID: 3092589
    [No Abstract] [Full Text] [Related]

  • 11. Chemoprevention of superficial bladder cancer.
    Kamat AM.
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):799-808. PubMed ID: 14686702
    [Abstract] [Full Text] [Related]

  • 12. [Prevention of recurrence in urinary bladder cancer--quo vadis?].
    Kriegmair M.
    Fortschr Med; 1989 Mar 15; 107(8):14-5. PubMed ID: 2707703
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Laser treatment of bladder cancer.
    Smith JA.
    Semin Urol; 1985 Feb 15; 3(1):2-9. PubMed ID: 3159062
    [No Abstract] [Full Text] [Related]

  • 16. Recurrency rate influencing effect on intravesical Lycurim treatment in transurethrally resected bladder tumours.
    Kondás J, Szentgyörgyi E.
    Ther Hung; 1983 Feb 15; 31(2):55-8. PubMed ID: 6571182
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.